BSR Biologics Register News
Document Actions
The report* showed a reduction of myocardial infarction in patients with rheumatoid arthritis who responded to TNF alpha blockade.
In other BSRBR news, following lengthy negotiations with Roche and the arc Epidemiology Unit, I can now confirm that BSR Biologics Register has been extended to include a study of the use of rituximab in the treatment of patients with rheumatoid arthritis. We are aiming to recruit 1,100 patients and anticipate that the vast majority will have failed a single TNF alfa blocking drug (as well as the more conventional disease modifying drugs).
Information about how to register your patients has been sent round to every rheumatology unit in the country, so do please start registering your patients as soon as possible.
David Isenberg, BSRBR Steering Committee
* Dixon W, Lunt M, Watson K, Hyrich K, BSRBR Control Centre Consortium, Symmons D on behalf of the BSR Biologics Register. The incidence of myocardial infarction is reduced in patients with rheumatoid arthritis who respond to anti-TNFα therapy. Arthritis Rheum. 2007;56:2905-12